Skip to content
6-K

Foreign Interim / Material

CELYAD ONCOLOGY SA

0001193125-23-228030

← back to feed
Filed
Sep 5, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q2 2023 · Jun 30, 2023 22.59M sh
Shares Diluted Q2 2023 · Jun 30, 2022 22.59M sh
Operating Cash Flow Q2 2023 · Jun 30, 2023 −€8.33M
Operating Cash Flow Q2 2023 · Jun 30, 2022 −€16.31M
Cash And Equivalents Q2 2023 · Jun 30, 2023 €4.98M
Cash And Equivalents Q2 2023 · Dec 31, 2022 €12.45M
Cash And Equivalents Q2 2023 · Jun 30, 2022 €14.39M
Cash And Equivalents Q2 2023 · Dec 31, 2021 €30.02M
Stockholders Equity Q2 2023 · Jun 30, 2023 €1.02M
Stockholders Equity Q2 2023 · Dec 31, 2022 €4.32M
Stockholders Equity Q2 2023 · Jun 30, 2022 €30.65M
Stockholders Equity Q2 2023 · Dec 31, 2021 €43.64M
Current Liabilities Q2 2023 · Jun 30, 2023 €6.09M
Current Liabilities Q2 2023 · Dec 31, 2022 €10.43M
Current Assets Q2 2023 · Jun 30, 2023 €7.69M
Current Assets Q2 2023 · Dec 31, 2022 €14.83M
Total Assets Q2 2023 · Jun 30, 2023 €12.18M
Total Assets Q2 2023 · Dec 31, 2022 €19.72M
Eps Basic Q2 2023 · Jun 30, 2023 −€0.17
Eps Basic Q2 2023 · Jun 30, 2022 −€0.62
Sga Expense Q2 2023 · Jun 30, 2023 €3.67M
Sga Expense Q2 2023 · Jun 30, 2022 €6.25M
Rd Expense Q2 2023 · Jun 30, 2023 €2.14M
Rd Expense Q2 2023 · Jun 30, 2022 €10.53M
Net Income Q2 2023 · Jun 30, 2023 −€3.74M
Net Income Q2 2023 · Dec 31, 2022 −€26.88M
Net Income Q2 2023 · Jun 30, 2022 −€14.06M
Operating Income Q2 2023 · Jun 30, 2023 −€3.75M
Operating Income Q2 2023 · Jun 30, 2022 −€14.08M
Gross Profit Q2 2023 · Jun 30, 2023 €0
Gross Profit Q2 2023 · Jun 30, 2022 €0
Cost Of Revenue Q2 2023 · Jun 30, 2023 €44K
Cost Of Revenue Q2 2023 · Jun 30, 2022 €0
Revenue Q2 2023 · Jun 30, 2023 €44K
Revenue Q2 2023 · Jun 30, 2022 €0